The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting
British Journal of Dermatology · 19.05.2025 · 192 (6) · 1096-1105
DOI: 10.1093/bjd/ljae470 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 28.11.2024. Verfasst von Karine Billard und 23 weiteren Autor:innen. Beteiligte Einrichtung: Service d'onco-dermatologie, Hôpital Saint Louis APHP, Paris, France. Hauptthemen laut MEDLINE: Melanoma, Nivolumab, Ipilimumab, Skin Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival (PFS) and numerically, although not statistically, superior overall survival (OS) for ipilimumab + nivolumab (I + N).
Objectives
The objective of this study was to compare the efficacy and safety of N with I + N as first-line treatment for metastatic melanoma in a real-world setting.
Methods
Patients were prospectively included in the French MelBase cohort from 2013 to 2022. Eligible patients were those in first-line treatment for stage IIIc or IV melanoma, undergoing immunotherapy with N or I + N. The primary endpoint was OS at 36 months. The secondary endpoints included PFS at 36 months, best radiological response, and safety analyses. We conducted a propensity score using the inverse probability of treatment weighting (IPTW) method to overcome the various confounding factors and also a subgroup analysis (brain metastasis, lactate dehydrogenase levels and BRAF mutation status).
Results
Patients were treated with N (n = 406) or I + N (n = 416). OS at 36 months was higher in the I + N group at 57.1% [95% confidence interval (CI) 50.7–64.2] than in the N group [46.6% (95% CI 41.6–52.1)]; hazard ratio (HR) 1.4 (95% CI 1.1–1.8). PFS at 36 months was significantly improved in the I + N group (42.3%) compared with the N group (21.9%), with a HR of 1.6 (95% CI 1.4–1.9). The objective response rate (ORR) was similar for the two groups (44%). The overall incidence of side-effects was comparable (82% vs. 84%), and severe toxicity (grade ≥ 3) was more frequent, although not significantly so, in the I + N arm vs. the N arm (41% vs. 29%).
Conclusions
Our results are consistent with those from the Checkmate 067 study, except for the ORR and the incidence of toxicities, which proved to be lower in our analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service d'onco-dermatologie, Hôpital Saint Louis APHP, Paris, France.
ORCID-Profile: Karine Billard, Florence Brunet-Possenti, Thierry Lesimple
Zitieren
APA
Billard, K., Mortier, L., Dereure, O., Dalac, S., Montaudié, H., Legoupil, D., Dutriaux, C., De Quatrebarbes, J., Maubec, E., Leccia, M. T., Granel-Brocard, F., Brunet-Possenti, F., Arnault, J. P., Gaudy-Marqueste, C., Pages, C., Saiag, P., L'Orphelin, J. M., Zehou, O., Lesimple, T., …, & Lebbé, C. (2025). The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting. British Journal of Dermatology, 192(6), 1096-1105. https://doi.org/10.1093/bjd/ljae470
Vancouver
Billard K, Mortier L, Dereure O, Dalac S, Montaudié H, Legoupil D, et al. The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting. British Journal of Dermatology. 2025;192(6):1096-1105. doi:10.1093/bjd/ljae470
BibTeX
@article{Billard2025,
author = {Billard, Karine and Mortier, Laurent and Dereure, Olivier and Dalac, Sophie and Montaudié, Henri and Legoupil, Delphine and Dutriaux, Caroline and De Quatrebarbes, Julie and Maubec, Eve and Leccia, Marie-Thérèse and Granel-Brocard, Florence and Brunet-Possenti, Florence and Arnault, Jean-Philippe and Gaudy-Marqueste, Caroline and Pages, Cecile and Saiag, Philippe and L'Orphelin, Jean-Matthieu and Zehou, Ouidad and Lesimple, Thierry and Allayous, Clara and Porcher, Raphael and Oriano, Bastien and Dalle, Stephane and Lebbé, Céleste},
title = {The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting},
journal = {British Journal of Dermatology},
year = {2025},
volume = {192},
number = {6},
pages = {1096--1105},
doi = {10.1093/bjd/ljae470}
}
EUVIMED